Evidence map›Paper›PMID 27251881›Full record

ArticleDalton transactions (Cambridge, England : 2003)2016

Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents.

S Ding, U Bierbach

Abstract read
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

S DingDepartment of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, USA. bierbau@wfu.edu.
U BierbachDepartment of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, USA. bierbau@wfu.edu and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA.

Funding

Novel DNA-metalating Hybrid Anticancer AgentsR01CA101880 · NCI · WAKE FOREST UNIVERSITY · PI BIERBACH, ULRICH · 2003 to 2012
$1.8M
NCI NIH HHS R01 CA101880
6 · The paper itself

Abstract

A versatile and efficient modular synthetic platform was developed for assembling multifunctional conjugates and targeted forms of platinum-(benz)acridines, a class of highly cytotoxic DNA-targeted hybrid agents. The synthetic strategy involved amide coupling between succinyl ester-modified platinum compounds (P1, P2) and a set of 11 biologically relevant primary and secondary amines (N1-N11). To demonstrate the feasibility and versatility of the approach, a structurally and functionally diverse range of amines was introduced. These include biologically active molecules, such as rucaparib (a PARP inhibitor), E/Z-endoxifen (an estrogen receptor antagonist), and a quinazoline-based tyrosine kinase inhibitor. Micro-scale reactions in Eppendorf tubes or on 96-well plates were used to screen for optimal coupling conditions in DMF solution with carbodiimide-, uronium-, and phosphonium-based compounds, as well as other common coupling reagents. Reactions with the phosphonium-based coupling reagent PyBOP produced the highest yields and gave the cleanest conversions. Furthermore, it was demonstrated that the chemistry can also be performed in aqueous media and is amenable to parallel synthesis based on multiple consecutive reactions in DMF in a "one-tube" format. In-line LC-MS was used to assess the stability of the conjugates in physiologically relevant buffers. Hydrolysis of the conjugates occurs at the ester moiety and is facilitated by the aquated metal moiety under low-chloride ion conditions. The rate of ester cleavage greatly depends on the nature of the amine component. Potential applications of the linker technology are discussed.

Indexed as

AcridinesAminesAntineoplastic AgentsDendrimersIndolesOrganophosphorus CompoundsPlatinumQuinazolinesTamoxifen4-hydroxy-N-desmethyltamoxifenAcridinesAminesAntineoplastic AgentsDendrimersIndolesOrganophosphorus CompoundsPAMAM StarburstPlatinumQuinazolinesrucaparibTamoxifen

Identifiers

PMID27251881
PMCPMC4987242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.